Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases
Journal of Cellular Biochemistry · 2023-09 · 124 (9) · 1223-1240
DOI: 10.1002/jcb.30468 ↗At a glance
Übersichtsarbeit in Journal of Cellular Biochemistry, published online on 2023-09-03. Written by Manzar Alam and 5 co-authors. Institution: Center for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Major MEDLINE topics: Neurodegenerative Diseases, Alzheimer Disease, Neoplasms. Cited 16 times so far (Crossref); 154 references. Funded by: Indian Council of Medical Research.
Abstract (original language)
Microtubule affinity‐regulating kinase 4 (MARK4) is a member of the Ser/Thr protein kinase family, phosphorylates the microtubule‐connected proteins and plays a vital role in causing cancers and neurodegenerative diseases. This kinase modulates multiple signaling pathways, including mammalian target of rapamycin, nuclear factor‐κB, and Hippo‐signaling, presumably responsible for cancer and Alzheimer's. MARK4 acts as a negative controller of the Hippo‐kinase cassette for promoting YAP/TAZ action, and the loss of MARK4 detains the tumorigenic properties of cancer cells. MARK4 is involved in tau hyperphosphorylation that consequently affects neurodegeneration. MARK4 is a promising drug target for cancer, diabetes, and Alzheimer's. Developing the potent and selective inhibitors of MAKR4 are promising in the therapeutic management of associated diseases. Despite its great significance, a few reviews are available to discuss its structure, function and clinical significance. In the current review, we aimed to provide detailed information on the structural features of MARK4 targeted in drug development and its role in various signaling pathways related to cancer and neurodegenerative diseases. We further described the therapeutic potential of MARK4 inhibitors in preventing numerous diseases. Finally, the updated information on MARK4 will be helpful in the further development of effective therapeutic molecules.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
- Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
- Department of Biochemistry, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
ORCID profiles: Asimul Islam, Md Imtaiyaz Hassan
Funding
- Indian Council of Medical Research
Cite
APA
Alam, M., Ahmed, S., Abid, M., Hasan, G. M., Islam, A., & Hassan, M. I. (2023). Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases. Journal of Cellular Biochemistry, 124(9), 1223-1240. https://doi.org/10.1002/jcb.30468
Vancouver
Alam M, Ahmed S, Abid M, Hasan GM, Islam A, Hassan MI. Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases. Journal of Cellular Biochemistry. 2023;124(9):1223-1240. doi:10.1002/jcb.30468
BibTeX
@article{Alam2023,
author = {Alam, Manzar and Ahmed, Sarfraz and Abid, Mohammad and Hasan, Gulam Mustafa and Islam, Asimul and Hassan, Md Imtaiyaz},
title = {Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases},
journal = {Journal of Cellular Biochemistry},
year = {2023},
volume = {124},
number = {9},
pages = {1223--1240},
doi = {10.1002/jcb.30468}
}
EUVIMED